Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

<< Previous

Bullboard Posts

Next >>

Post by R_J_on Jul 01, 2020 5:21am

194 Views

Post# 31211435

End of First Half - 2020

End of the First Half Report for 2020 for Anavex Life Sciences Corp.
-
AVXL closed on 06/30/2020 at US$4.92
AVXL closed on 12/31/2019 at US$2.59
-
This is a 90.0%, a US$2.33, GAIN for the first half of 2020.
-
S&P 500 Index for first half of 2020.
Closed on 2020/06/30 @ 3100.2
Closed on 2019/12/31 @ 3230.7
This is a loss for the 1st Half of 4.0%, or 130.4
Its MA(200) ended the 1st Half @ 3021.6
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's MA(200) ended June at $3.30
AVXL is now 49.1% above its MA(200).
-
Who is the Big Cheese at AVXL?
Christopher U. Missling, PhD, President & CEO
-
RJ

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks